Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: A cautionary tale for dermatologists

Archives of Dermatology

Volumn 145, Issue 8, 2009, Pages 937-942

  Korman, Benjamin D ^b   Tyler, Kenneth L ^b   Korman, Neil J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; EFALIZUMAB; INTERFERON; INTERLEUKIN 2 DERIVATIVE; MEFLOQUINE; MIRTAZAPINE; NATALIZUMAB; PREDNISONE; RITUXIMAB; TOPOTECAN; VINCRISTINE SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DEMYELINATION; DISEASE ASSOCIATION; DRUG MONITORING; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; MULTIPLE SCLEROSIS; NON INVASIVE PROCEDURE; NONHODGKIN LYMPHOMA; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OPPORTUNISTIC INFECTION; PATHOGENESIS; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS VULGARIS; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT WITHDRAWAL; VIRUS INFECTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; RISK FACTORS; SKIN DISEASES;

EID: 68949107635     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.175     Document Type: Note

References (58)

1. Padgett BL, Zurhein GM, Walker DL, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet. 1971;297(7712):1257-1260. doi:10.1016/S0140-6736(71)91777-6.
2. Åström KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain. 1958;81(1):93-111.
3. Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology. 1991;41(11):1733-1736.
4. Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77-83.
5. Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin. 2008;26(3):833-854, x-xi.
6. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
7. US Department of Health and Human Services. FDA approves updated labeling for psoriasis drug Raptiva: safety concerns drove labeling changes. FDA Web site. October 16, 2008. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2008/ucm116969.htm. Accessed December 15, 2008.
8. Holman RC, Török TJ, Belay ED, Janssen RS, Schonberger LB. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology. 1998;17(6):303-309.
9. Dworkin MS, Wan PC, Hanson DL, Jones JL. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis. 1999;180(3):621-625.
10. Aksamit AJ. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist. 2006;12(6):293-298.
11. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005;17(11):658-665.
12. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008;67(suppl 3):iii64-iii65.
13. US Department of Health and Human Services. Natalizumab (marketed as Tysabri) information. FDA Web site. August 2008. http://www.fda.gov/Drugs/ DrugSafety/DrugSafetyNewsletter/ucm107188.htm. Accessed March 1, 2009.
14. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353(4):362-368.
15. Khalili K, White MK, Lublin F, Ferrante P, Berger JR. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology. 2007;68(13):985-990.
16. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(suppl 2):S180-S186.
17. Pietropaolo V, Videtta M, Fioriti D, et al. Rearrangement patterns of JC virus noncoding control region from different biological samples. J Neurovirol. 2003;9(6):603-611.
18. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol. 2008;64(4):379-387.
19. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol. 2004;17(3):365-370.
20. Koralnik IJ, Schellingerhout D, Frosch MP. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises: case 14-2004: a 66-year-old man with progressive neurologic deficits. N Engl J Med. 2004;350(18):1882-1893.
21. Demeter LJC. BK, and other polyomaviruses: progressive multifocal leukoencephalopathy. In: Mandell GG, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA: Churchill Livingstone; 2000:1645-1654.
22. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4(1):59-68.
23. Whiteman ML, Post MJ, Berger JR, Tate LG, Bell MD, Limonte LP. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology. 1993;187(1):233-240.
24. Demeter LM. JC, BK, and other polyomaviruses: progressive multifocal leukoencephalopathy. In: Mandell GG, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:1856-1863.
25. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924-933.
26. Post MJ, Yiannoutsos C, Simpson D, et al; AIDS Clinical Trials Group, 243 Team. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AJNR Am J Neuroradiol. 1999;20(10):1896-1906.
27. Cinque P, Vago L, Dahl H, et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS. 1996;10(9):951-958.
28. García De Viedma D, Diaz Infantes M, Miralles P, et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin Infect Dis. 2002;34(12):1568-1575.
29. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56(7):2116-2128.
30. Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis. 2006;65(suppl 3):iii48-iii53.
31. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008;30(1-2):90-98.
32. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402-409.
33. Eng PM, Turnbull BR, Cook SF, Davidson JE, Kurth T, Seeger JD. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology. 2006;67(5):884-886.
34. García-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005;80(4):271-281.
35. Yokoyama H, Watanabe T, Maruyama D, Kim SW, Kobayashi Y, Tobinai K. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol. 2008;88(4):443-447.
36. Roche Laboratories Inc. Important changes in the CellCept® (mycophenolate mofetil) prescribing information: reports of progressive multifocal leukoencephalopathy (PML) in patients treated with CellCept. June 2008. http://www.rocheusa.com/products/cellcept/CellceptLetterPML-May2008.pdf. Accessed March 1, 2009.
37. US Department of Health and Human Services. Information on mycophenolate mofetil (marketed as CellCept) and mycophenolic acid (marketed as Myfortic). FDAWebsite. May 16, 2008. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm111294.htm. Accessed March 1, 2009.
38. Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008;86(10):1474-1478.
39. Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J. 2006;12(1):3 http://dermatology.cdlib.org/121/reviews/rituxab/ scheinfeld.html. Accessed March 1, 2009.
40. Genentech Inc. Important drug warning: updated safety information. http://www.gene.com/gene/products/information/pdf/rituxan-DHCP-Letter.pdf. Accessed March 1, 2009.
41. US Department of Health and Human Services. Rituximab (marketed as Rituxan) information. FDA Web site. December 18, 2006. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109106.htm. Accessed March 1, 2009.
42. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4):369-374.
43. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375-381.
44. Greenlee JE. Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications. Int MS J. 2006;13(3):100-107.
45. Tysabri update. http://library.corporate-ir.net/library/14/148/148682/ items/320749/FEBA1E02-71F0-47D7-9FD5-407EB4D7F837-TysabriUpdate.13Feb2009.pdf. Accessed March 1, 2009.
46. Genentech Inc. Important drug warning regarding Raptiva (efalizumab). November 2008. http://www.gene.com/gene/products/information/pdf/raptiva-dhcp- pml2.pdf. Accessed March 1, 2009.
47. Genentech Inc. Important drug warning regarding Raptiva (efalizumab). February 10, 2009. http://www.gene.com/gene/products/information/pdf/raptiva- dhcp-pml3.pdf. Accessed March 1, 2009.
48. US Department of Health and Human Services. FDA advises public of serious adverse event with psoriasis drug Raptiva. FDA Web site. February 19, 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149528.htm. Accessed June 15, 2009.
49. Genentech Inc. Genentech announces voluntary withdrawal of Raptiva from the US Market. April 18, 2009. http://www.gene.com/gene/news/press-releases/ display.do?method=detail&id=12047. Accessed June 12, 2009.
50. Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 2007;96(1):128-130.
51. Rahmlow M, Shuster EA, Dominik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol. 2008;65(11):1538-1539.
52. Schuuring J, Wesseling P, Verrips A. Severe tacrolimus leukoencephalopathy after liver transplantation. AJNR Am J Neuroradiol. 2003;24(10):2085-2088.
53. Shprecher D, Frech T, Chin S, Eskandari R, Steffens J. Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose. Lupus. 2008;17(11):1029-1032.
54. Cotone C, Lucentini M, García G, Aníbal Molina H. Psoriasis and progressive multifocal leukoencephalopathy in AIDS [in Spanish]. Rev Clin Esp. 1992;191(5):285-286.
55. Carey W, Glazer S, Gottlieb A, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006;54(4)(suppl 1):S171-S181.
56. Khanna N, Wolbers M, Mueller NJ, et al; Swiss HIV Cohort Study. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol. 2009;83(9):4404-4411.
57. DuPasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain.2004;127(pt 9):1970-1978.
58. Gasnault J, Kahraman M, de Goër de Herve MG, Durali D, Delfraissy JF, Taoufik Y. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS. 2003;17(10):1443-1449.